p38-MAPK inhibition and endotoxin induced tubular dysfunction in men

Abstract

Background: To evaluate the possibility of preventing endotoxin induced renal damage by p38-MAPK inhibition in a human model.

Design and Methods: Twenty-one healthy young male volunteers received 4 ng/kg Escherichia coli endotoxin as a single dose. Four groups of volunteers received an oral dose of placebo or 350, 700 or 1400 mg RWJ-67657, a p38-MAPK inhibitor, 20 min before endotoxin infusion. Urine samples were collected at set time intervals. The urinary excretion rate of β₂-microglobulin and N-acetyl-β-D-glucosaminidase, as indicators of tubular dysfunction was determined.

Results: There was a significant increase of β₂-microglobulin and N-acetyl-β-D-glucosaminidase urine excretion rate after endotoxin infusion in the placebo group. p38-MAPK inhibition prevented the increase of markers for tubulopathy.

Conclusions: Endotoxin infusion induces measurable tubular damage. Blocking the p38-MAPK may prevent this damage. The mechanism is unclear, but blocking TNF-α release is a possible explanation.

Keywords

Endotoxin renal failure p38-MAPK inhibition tubulopathy

References

Wadsworth SA , Cavender DE , Beers SA et al. RWJ-67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 1999; 291: 680—687.

Fijen JW , Tulleken JE , Kobold AC et al. Inhibition of p38 mitogen-activated protein kinase: dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans. Crit Care Med 2002; 30: 841—845.

Fijen JW , Kobold AC , de Boer P. et al. Leukocyte activation and cytokine production during experimental human endotoxemia. Eur J Intern Med 2000; 11: 89—95.

Fijen JW , Zijlstra JG , de Boer P. et al. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol 2001; 124: 16—20.

Faas MM , Moes H. , Fijen JW et al. Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness. Clin Exp Immunol 2002; 127: 337—343.

Iwami KI , Matsuguchi T. , Masuda A. et al. Naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol 2000; 165: 6682—6686.

Hoekman K. , Van Nieuwkoop JA , Willemze R. The significance of beta-2 microglobulin in clinical medicine. Neth J Med 1985; 28: 551—557.

Price RG

Measurement of N-acetyl-beta-glucosaminidase and its isoenzymes in urine methods and clinical applications. Eur

J Clin Chem Clin Biochem 1992; 30: 693—705.

Tassi C. , Abbritti G. , Mancuso F. et al. Activity and isoenzyme profile of N-acetyl-beta-D-glucosaminidase in urine from workers exposed to cadmium. Clin Chim Acta 2000; 299: 55—64.

10.

Khan RZ , Badr KF Endotoxin and renal function: perspectives to the understanding of septic acute renal failure and toxic shock. Nephrol Dial Transplant 1999; 14: 814—818.

11.

Thijs A. , Thijs LG Pathogenesis of renal failure in sepsis. Kidney Int Suppl 1998; 66: S34—S37.

12.

Ueda N. , Shah SV Tubular cell damage in acute renal failureapoptosis, necrosis, or both. Nephrol Dial Transplant 2000; 15: 318—323.

13.

Knotek M. , Rogachev B. , Wang W. et al. Endotoxemic renal failure in mice: role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 2001; 59: 2243—2249.

14.

Cunningham PN , Dyanov HM , Park P. et al. Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 2002; 168: 5817—5823.